TY - JOUR
T1 - Establishment of a rapid and footprint-free protocol for differentiation of human embryonic stem cells into pancreatic endocrine cells with synthetic mRNAs encoding transcription factors 10 Technology 1004 Medical Biotechnology
AU - Ida, Hideomi
AU - Akiyama, Tomohiko
AU - Ishiguro, Keiichiro
AU - Goparaju, Sravan K.
AU - Nakatake, Yuhki
AU - Chikazawa-Nohtomi, Nana
AU - Sato, Saeko
AU - Kimura, Hiromi
AU - Yokoyama, Yukihiro
AU - Nagino, Masato
AU - Ko, Minoru S.H.
AU - Ko, Shigeru B.H.
N1 - Funding Information:
This study was supported by JSPS KAKENHI Grant Number JP15H04812, JP16K15433 to SBHK, and the CREST program from the Japan Science and Technology Agency (JST) and the Research Center Network for Realization of Regenerative Medicine, Japan Agency for Medical Research and Development (AMED) to MSHK. This study was supported by the Keio University Medical Science Fund—The Mitsunada Sakaguchi Laboratory.
Funding Information:
This study was supported by JSPS KAKENHI Grant Number JP15H04812, JP16K15433 to SBHK, and the CREST program from the Japan Science and Technology Agency (JST) and the Research Center Network for Realization of Regenerative Medicine, Japan Agency for Medical Research and Development (AMED) to MSHK. This study was supported by the Keio University Medical Science Fund-The Mitsunada Sakaguchi Laboratory.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/10/25
Y1 - 2018/10/25
N2 - Background: Transplantation of pancreatic β cells generated in vitro from pluripotent stem cells (hPSCs) such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) has been proposed as an alternative therapy for diabetes. Though many differentiation protocols have been developed for this purpose, lentivirus-mediated forced expression of transcription factors (TF) - PDX1 and NKX6.1 - has been at the forefront for its relatively fast and straightforward approach. However, considering that such cells will be used for therapeutic purposes in the future, it is desirable to develop a procedure that does not leave any footprint on the genome, as any changes of DNAs could potentially be a source of unintended, concerning effects such as tumorigenicity. In this study, we attempted to establish a novel protocol for rapid and footprint-free hESC differentiation into a pancreatic endocrine lineage by using synthetic mRNAs (synRNAs) encoding PDX1 and NKX6.1. We also tested whether siPOU5F1, which reduces the expression of pluripotency gene POU5F1 (also known as OCT4), can enhance differentiation as reported previously for mesoderm and endoderm lineages. Methods: synRNA-PDX1 and synRNA-NKX6.1 were synthesized in vitro and were transfected five times to hESCs with a lipofection reagent in a modified differentiation culture condition. siPOU5F1 was included only in the first transfection. Subsequently, cells were seeded onto a low attachment plate and aggregated by an orbital shaker. At day 13, the degree of differentiation was assessed by quantitative RT-PCR (qRT-PCR) and immunohistochemistry for endocrine hormones such as insulin, glucagon, and somatostatin. Results: Both PDX1 and NKX6.1 expression were detected in cells co-transfected with synRNA-PDX1 and synRNA-NKX6.1 at day 3. Expression levels of insulin in the transfected cells at day 13 were 450 times and 14 times higher by qRT-PCR compared to the levels at day 0 and in cells cultured without synRNA transfection, respectively. Immunohistochemically, pancreatic endocrine hormones were not detected in cells cultured without synRNA transfection but were highly expressed in cells transfected with synRNA-PDX1, synRNA-NKX6.1, and siPOU5F1 at as early as day 13. Conclusions: In this study, we report a novel protocol for rapid and footprint-free differentiation of hESCs to endocrine cells.
AB - Background: Transplantation of pancreatic β cells generated in vitro from pluripotent stem cells (hPSCs) such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) has been proposed as an alternative therapy for diabetes. Though many differentiation protocols have been developed for this purpose, lentivirus-mediated forced expression of transcription factors (TF) - PDX1 and NKX6.1 - has been at the forefront for its relatively fast and straightforward approach. However, considering that such cells will be used for therapeutic purposes in the future, it is desirable to develop a procedure that does not leave any footprint on the genome, as any changes of DNAs could potentially be a source of unintended, concerning effects such as tumorigenicity. In this study, we attempted to establish a novel protocol for rapid and footprint-free hESC differentiation into a pancreatic endocrine lineage by using synthetic mRNAs (synRNAs) encoding PDX1 and NKX6.1. We also tested whether siPOU5F1, which reduces the expression of pluripotency gene POU5F1 (also known as OCT4), can enhance differentiation as reported previously for mesoderm and endoderm lineages. Methods: synRNA-PDX1 and synRNA-NKX6.1 were synthesized in vitro and were transfected five times to hESCs with a lipofection reagent in a modified differentiation culture condition. siPOU5F1 was included only in the first transfection. Subsequently, cells were seeded onto a low attachment plate and aggregated by an orbital shaker. At day 13, the degree of differentiation was assessed by quantitative RT-PCR (qRT-PCR) and immunohistochemistry for endocrine hormones such as insulin, glucagon, and somatostatin. Results: Both PDX1 and NKX6.1 expression were detected in cells co-transfected with synRNA-PDX1 and synRNA-NKX6.1 at day 3. Expression levels of insulin in the transfected cells at day 13 were 450 times and 14 times higher by qRT-PCR compared to the levels at day 0 and in cells cultured without synRNA transfection, respectively. Immunohistochemically, pancreatic endocrine hormones were not detected in cells cultured without synRNA transfection but were highly expressed in cells transfected with synRNA-PDX1, synRNA-NKX6.1, and siPOU5F1 at as early as day 13. Conclusions: In this study, we report a novel protocol for rapid and footprint-free differentiation of hESCs to endocrine cells.
KW - Embryonic stem cells
KW - Endocrine differentiation
KW - NKX6.1
KW - PDX1
KW - Pancreatic β cells
KW - Synthetic mRNAs
KW - Transcription factors
KW - siPOU5F1
UR - http://www.scopus.com/inward/record.url?scp=85055627990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055627990&partnerID=8YFLogxK
U2 - 10.1186/s13287-018-1038-3
DO - 10.1186/s13287-018-1038-3
M3 - Article
C2 - 30359326
AN - SCOPUS:85055627990
SN - 1757-6512
VL - 9
JO - Stem Cell Research and Therapy
JF - Stem Cell Research and Therapy
IS - 1
M1 - 277
ER -